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Abstract
Inhibition of the proteasome is a widely used strategy for treating multiple myeloma that takes advantage of the
heavy secretory load that multiple myeloma cells (MMCs) have to deal with. Resistance of MMCs to proteasome
inhibition has been linked to incomplete disruption of proteasomal endoplasmic-reticulum (ER)-associated
degradation (ERAD) and activation of non-proteasomal protein degradation pathways. The ATPase p97 (VCP/
Cdc48) has key roles in mediating both ERAD and non-proteasomal protein degradation and can be targeted
pharmacologically by small molecule inhibition. In this study, we compared the effects of p97 inhibition with
Eeyarestatin 1 and DBeQ on the secretory apparatus of MMCs with the effects induced by the proteasome inhibitor
bortezomib, and the effects caused by combined inhibition of p97 and the proteasome. We found that p97 inhibition
elicits cellular responses that are different from those induced by proteasome inhibition, and that the responses differ
considerably between MMC lines. Moreover, we found that dual inhibition of both p97 and the proteasome terminally
disrupts ER configuration and intracellular protein metabolism in MMCs. Dual inhibition of p97 and the proteasome
induced high levels of apoptosis in all of the MMC lines that we analysed, including bortezomib-adapted AMO-1 cells,
and was also effective in killing primary MMCs. Only minor toxicity was observed in untransformed and non-secretory
cells. Our observations highlight non-redundant roles of p97 and the proteasome in maintaining secretory
homeostasis in MMCs and provide a preclinical conceptual framework for dual targeting of p97 and the proteasome
as a potential new therapeutic strategy in multiple myeloma.
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Introduction
Multiple myeloma (MM) is a tumour of transformed plasma
cells, terminally differentiated B cells that are highly specialised
to synthesise and secrete large amounts of immunoglobulins
(Ig) [1]. The production of large quantities of secreted protein
places a substantial strain on the protein-folding machinery and
can result in the accumulation of misfolded/unfolded proteins,
triggering the unfolded protein response (UPR). The UPR is a
fundamental cellular process that acts to maintain secretory
homeostasis by attenuating overall protein translation,
expanding the endoplasmic reticulum (ER), and increasing ER-
associated protein degradation (ERAD) of misfolded proteins in
the cytosol by the proteasome [2-4]. Failure of the UPR results
in overwhelming ER stress and apoptosis [4].
Plasma cells and MM cells (MMCs) have a well-developed
secretory apparatus to accommodate Ig secretion but are
nevertheless highly sensitive to agents that interfere with
intracellular protein metabolism [5-7]. This forms the basis for
selective targeting of MMCs by the proteasome inhibitor
bortezomib, which is widely used for the treatment of MM [8].
The combined findings of several studies suggest that the
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preferential toxicity of proteasome inhibitors to MMCs can be
attributed, to a large extent, to ERAD impairment and
overwhelming ER stress [9-12]. Primary or acquired resistance
of MMCs to bortezomib is an important clinical problem and
has been linked to incomplete ERAD disruption and the
activation of alternative protein degradation pathways, such as
autophagy and aggresome formation [5,13-15]. This makes it
important to develop therapeutic approaches that give more
effective disruption of secretory homeostasis in MMCs [1].
Prior to proteasomal degradation, misfolded proteins are
exported from the ER lumen to the cytosolic side of the ER,
where they are earmarked for degradation by poly-
ubiquitination [16]. This acts as a signal for binding of the
cytosolic ATPase, p97 (also known as valosin-containing
protein, VCP; or Cdc48), which delivers the ubiquitinated
protein to the proteasome by translating ATP hydrolysis into
mechanical force [17-21]. Hence, p97 has a central role in
ERAD and this role is closely linked to the proteasome.
However, like the proteasome, p97 also mediates the
degradation of non-secretory proteins that regulate a variety of
cellular functions [22-25]. Inhibitors of p97, were recently
reported to kill cancer cells by mechanisms that are related to
disruption of the secretory apparatus [26-30]. Eeyarestatin 1
(Eer1), which binds to both p97 and the ER membrane,
preferentially induces cancer cell death by ERAD disruption
and effects that are similar to those induced by bortezomib,
including ER stress-induced transcriptional up-regulation of
NOXA and induction of CHOP [26,28]. N2,N4-
dibenzylquinazoline-2,4-diamine (DBeQ), a reversible inhibitor
of the p97 ATPase activity, was found to be a potent activator
of caspases in cancer cells and to inhibit both ERAD and
autophagosome maturation [26,27]. Furthermore, there is
evidence that sorafenib, a multikinase inhibitor of the
Raf/MEK/ERK pathway and of tyrosine kinase receptors,
induces cancer cell death by preventing p97 tyrosine
phosphorylation and consecutive disruption of secretory
homeostasis [30,31]. Thus, p97 inhibition has the potential to
overcome some limitations of proteasome inhibition as an anti-
cancer strategy, particularly in secretory cancers such as MM
[32,33].
The essential roles of p97 and the proteasome in regulating
protein degradation, which are closely linked in ERAD but also
show a considerable degree of non-redundancy, open up the
possibility that simultaneous inhibition of p97 and the
proteasome could be highly efficient in disrupting secretory
homeostasis in MMCs. Here we demonstrate that inhibitors of
either p97 or the proteasome have quite different effects on the
secretory apparatus in MMCs, and that these effects vary
substantially between different MMC lines, and between MMCs
and non-secretory or non-transformed cells. Moreover, we
show that dual inhibition of p97 and the proteasome has
dramatic effects on ER morphology and protein turnover that
are selective for MMCs and are very different from the effects
of single inhibition with either drug. Our results provide a
conceptual preclinical framework for simultaneous targeting of
p97 and the proteasome as a potential new therapeutic
strategy in multiple myeloma.
Materials and Methods
Ethics statement
Bone marrow myeloma cells, bone marrow mesenchymal
stroma cells, and skin fibroblasts were collected at the Imperial
College London Centre for Haematology after approval by the
National Research Ethics Service Committee East of England
– Cambridge Central and obtaining signed informed consent in
accordance with the Declaration of Helsinki.
Cell culture and reagents
The human MMC lines OPM-2, RPMI 8226, U-266, KMS-11,
and parental/bortezomib-adapted AMO-1 have been described
previously [7,15]. Primary MMCs were isolated from bone
marrow aspirates using CD138 microbeads and MACS
columns (Miltenyi) and cultured as MMC lines with the addition
of 10ng/ml human recombinant interleukin (IL)-6 (Peprotech).
Primary human skin fibroblasts and peripheral blood
mononuclear cells were cultured in the same medium but
without IL-6. Eer1 (Tocris), DBeQ (Cambridge Bioscience),
zVADfmk (Calbiochem), SP600125 (Sigma), and bortezomib
(Velcade®, Millenium) were stored in single-use aliquots at
-20°C.
Analysis of apoptosis
Apoptosis was assessed by staining with Annexin V-FITC
and propidium iodide (PI; BD Pharmingen) as previously
described [7]. Cells negative for Annexin V-FITC and PI were
classified as live.
Immunoblotting
Whole cell lysates were prepared as previously described
[7]. Primary antibodies were directed against Akt, phospho-Akt
(Ser473), caspase-3, p58IPK, GRP94, eIF2α, phospho-eIF2α
(Ser51), S6 ribosomal protein, phospho-S6 ribosomal protein
(Ser235/236), β-tubulin (all from Cell Signaling Technologies),
and ubiquitin (P4D1, Santa Cruz Biotechnology).
Qualitative and quantitative ER staining
Cells were incubated with 100nM BODIPY FL brefeldin A
(BFA-BODIPY, Invitrogen) at 37°C for 40 minutes in the dark,
washed and resuspended in phosphate-buffered saline (PBS),
and analysed immediatedy on a BD LSR II flow cytometer. For
morphological ER analysis, cells were incubated in medium
with 1µM ER Tracker Blue-White DPX (Molecular Probes) at
37°C for 15 minutes, pelleted, and resuspended in 50µl
medium. The cell suspension was applied to an imaging
chamber [34], and imaged with a Zeiss LSM510 or Leica SP5
confocal microscope.
Electron microscopy
1x107 cells were fixed, washed, post-fixed and embedded as
previously described [35]. Ultrathin sections were cut on a
Leica Ultracut R microtome, stained with Reynolds lead citrate,
and observed in a Jeol JEM 1200EX II transmission electron
microscope.
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Results
Dual inhibition of p97 and the proteasome is highly
toxic to myeloma cells
We first determined the apoptotic sensitivity of a panel of
human MMC lines to bortezomib and the p97 inhibitor Eer1
(Figure 1A). The result of this analysis shows that OPM-2 cells
were the most resistant to both bortezomib and Eer1, while
KMS-11 cells were the most sensitive to both inhibitors. Next,
we investigated whether simultaneous inhibition of p97 and of
the proteasome increases MMC death compared to separate
inhibition. We treated the panel of MMC lines with
concentrations of bortezomib (5nM) and Eer1 (5µM) that have
been shown to be pharmacologically effective in cancer cells,
including malignant B cells, and fibroblasts [11,29,36-38]. . In
addition, we found that a 2-hour treatment with 5nM of
bortezomib blocked chymotrypsin-like proteasome activity by
approximately 80% in OPM-2 cells, and that an 8-hour
treatment of KMS-11 cells with Eer1, but not with bortezomib,
significantly up-regulated HMOX1 levels, as demonstrated
previously (data not shown) [11]. At these concentrations, and
at the time-points studied, bortezomib and Eer1 had little
impact on MMC line survival on their own (Figure 1B).
However, dual p97/proteasome inhibition induced apoptosis
very effectively in all MMC lines investigated (Figure 1B).
Importantly, OPM-2 cells, which are resistant to bortezomib
and characterised by abnormalities that confer poor outcome in
patients, including t(4;14) and constitutive Akt activation, were
also killed effectively by dual p97/proteasome inhibition [39,40].
To extend these findings, we treated the bortezomib-adapted
MMC line AMO-1a, which we cultured in the presence of
primary human bone marrow stroma cells to confer further pro-
survival signals, with bortezomib and Eer1. We also tested the
effect of separate and dual p97/proteasome inhibition on
patient-derived MMCs grown in the presence of IL-6, and on
healthy donor peripheral blood mononuclear cells (PBMNCs).
While dual p97/proteasome inhibition effectively killed both the
AMO-1a cell line and the primary MMCs, it was substantially
less toxic against PBMNCs (Figure 1C). These findings
demonstrate that combined p97/proteasome inhibition is highly
toxic to MMCs, including MMC lines with primary and
secondary resistance to bortezomib.
Increased intracellular levels of ubiquitinated proteins are
considered to indicate impaired protein degradation by the
proteasomal machinery [5,15,41]. To test how separate and
combined inhibition of p97 and the proteasome affects protein
degradation, we quantified the levels of ubiquitinated proteins
in whole cell extracts from four MMC lines (Figure 1D). Dual
inhibition of p97 and the proteasome led to increased levels of
ubiquitinated proteins in all MMC lines tested, indicating
effective disruption of gross protein degradation. However, an
increased effect of dual over separate inhibition on levels of
ubiquitinated proteins was only observed in two lines (OPM-2
and U-266). It is also worth noting that bortezomib induced an
increase in ubiquitinated proteins only in OPM-2 cells, while
inhibition of p97 with Eer1 led to increased levels of
ubiquitinated proteins in the RPMI8226, U-266, and KMS-11
cells. Of particular importance is the finding that increased
levels of ubiquitinated proteins after separate inhibition did not
generally correlate with cell death (Figure 1B). This observation
strongly suggests that additional mechanisms are involved in
the induction of cell death by inhibitors of ERAD pathways.
Combined inhibition of p97 and the proteasome
drastically disrupts ER configuration in MMCs
Inhibitors of the proteasome and of p97 cause ER stress in
MM and other tumour cells, and ER stress is known to induce
changes in ER structure [9-11,26,42-44]. To investigate the
effects of separate and combined inhibition of p97 and the
proteasome on ER structure in MMCs, we visualised the ER of
MMC lines after staining with the fluorescent ER dye ER
Tracker Blue-White DPX (Figure 2A and Figure S1). In most of
the control cells, the ER was visible as elongated tubular
structures with some small globular regions. Bortezomib did not
cause any substantial changes in ER structure, although the
ER appeared to be slightly more densely packed in some cells.
However, treatment with the p97 inhibitor Eer1 had a clear
effect on the ER. Most of the tubular ER was lost, and small to
medium-sized vesicular and globular structures were instead
observed. Dual inhibition with bortezomib and Eer1 caused a
different and dramatic effect in that large parts of the ER were
transformed into medium-sized to large vacuoles. This
vacuolisation of the ER was not observed after treatment with
high doses of bortezomib, Eer1, or tunicamycin (Figure S2),
indicating that the changes were not caused by overwhelming
ER stress generated by an additive effect of the two inhibitors.
Furthermore, pre-incubation with the pan-caspase inhibitor
zVADfmk did not abrogate ER vacuolisation, indicating that it
did not occur as an unspecific consequence of apoptotic
signalling (Figure S2).
To further investigate the changes in ER configuration we
used transmission electron microscopy (TEM) of OPM-2 cells
(Figure 2B and Figure S3), which showed results that were
consistent with our findings obtained by staining with ER
Tracker Blue-White DPX. The TEM analysis of untreated cells
showed the expected elongated and narrow tubular ER
structures with ribosomes attached to the cytosolic ER surface.
Bortezomib did not have a uniformly discernible impact on ER
structure, although the ER appeared slightly distended and less
elongated in some cells. Inhibition of p97 with Eer1 did have an
impact on ER morphology at the level of ultrastructure, giving
rise to relatively short and moderately dilated tubular structures
in most cells. Dual inhibition had a much more dramatic effect
with the ER appearing predominantly as very large vacuoles in
the majority of cells. Dual p97/proteasome inhibition also
resulted in an empty appearance of the ER lumen, and
ribosomes were largely absent from the cytosolic surface of the
ER. The observation that the perinuclear space was also
substantially dilated, had the same empty appearance and
showed loss of ribosomes from its surface as the vacuoles,
provides strong support for the notion that the vacuoles are
indeed derived from the ER. The finding that most cells
presenting with vacuolised ER did not show any apoptotic
chromatin condensation further indicates that the changes in
ER morphology are unlikely to be unspecific consequences of
apoptotic signalling.
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We next investigated how dual p97/proteasome inhibition
affects cellular ER content by staining OPM-2 cells with the
fluorescent brefeldin A derivative, BFA-BODIPY (Figure 2C),
and immunoblotting for key ER luminal chaperones (Figure 2D)
[45]. While bortezomib treatment increased the amount of ER
stained by BFA-BODIPY by approximately 40% in OPM-2 cells,
Eer1 on its own had no discernible impact. Dual p97/
proteasome inhibition not only blocked the increase in BFA-
BODIPY staining that was induced by bortezomib, but reduced
it compared to control cells. Consistent with these findings,
immunoblotting showed an increase in the levels of the ER
lumenal chaperones, p58IPK (DNAJC3) and GRP94, after
Figure 1.  Dual p97 and proteasome inhibition induces high levels of apoptosis and disrupts protein degradation in
MMCs.  (A) A panel of human MMC lines were treated with the indicated concentrations of bortezomib (BTZ) or Eer1 for the
indicated time. The proportion of live cells relative to DMSO-treated controls was determined by staining with Annexin V-FITC and
PI (mean and SEM of 3 independent experiments). (B) MMC lines were treated with the indicated concentrations of BTZ and Eer1
for 48h (OPM-2, RPMI 8226) or 24h (U-266, KMS-11) and the proportion of live cells compared to controls determined as in A (*p<.
05, **p<.001, two-sided student’s t-test). (C) BTZ-adapted AMO-1 MMCs co-cultured with human bone marrow MSCs, primary
MMCs grown in the presence of IL-6, and healthy donor PBMNCs were subjected to single and dual inhibition with Bortezomib and
Eer1 (the median of 3 technical replicates is shown). (D) Immunoblotting for ubiquitinated proteins and tubulin (loading control)
carried out on whole cell extracts prepared from MMC lines treated with bortezomib, Eer1, or both inhibitors, for 24h (14h in KMS-11
cells due to their higher apoptotic sensitivity).
doi: 10.1371/journal.pone.0074415.g001
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Figure 2.  Combined inhibition of p97 and the proteasome dramatically affects ER configuration.  (A) RPMI 8226 myeloma
cells were stained with ER Tracker Blue-White DPX following treatment for 24h with bortezomib (BTZ; 5nM), Eer1 (5µM), or both.
Representative confocal microscopic images show minor ER alterations after BTZ treatment, transformation of tubule-lamellar into
globular ER structures after treatment with Eer1, and widespread ER vacuolisation after dual treatment. (B) Representative electron
microscopic images of OPM-2 cells after treatment with BTZ (5nM), Eer1 (5µM), or BTZ and Eer1, for 24h. Arrows indicate classical
ER in control cells, black arrowheads indicate moderately dilated and disrupted ER in Eer1-treated cells, and open arrowheads
indicate vacuolised ER with reduced ribosomes on the cytosolic ER surface. Another cell treated with Eer1 and BTZ is shown at
lower magnification (right panel). Areas of dilated perinuclear space are indicated by asterisks. Nu, nucleus. (C) BTZ and Eer1 have
different effects on ER volume as shown by staining of OPM-2 cells with BFA-BODIPY after treatment for 24h with BTZ (5nM), Eer1
(5µM), or with BTZ and Eer1. A representative histogram (left panel) and the mean and SEM of 6 experiments (right panel) are
shown (*p<.05, **p<.001, two-sided student’s t-test). (D) Immunoblotting for lumenal ER chaperones and tubulin (loading control)
was carried out on whole cell extracts prepared from OPM-2 cells treated as in (C).
doi: 10.1371/journal.pone.0074415.g002
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proteasome inhibition, and a decrease after dual ERAD
inhibition, while Eer1 had no detectable effect on the levels of
either protein. Together, these observations indicate that
bortezomib increases ER content in MMCs, whereas inhibition
of p97 with Eer1 causes moderate alterations to ER structure.
In contrast, dual p97/proteasome inhibition drastically alters the
configuration of the ER.
Dual inhibition of p97 and the proteasome disrupts key
pathways that control survival, death, and protein
synthesis and induces predominantly caspase-
dependent cell death in MMCs
Next, we investigated the impact of single (bortezomib or
Eer1 alone) and dual p97/proteasome inhibition on key
signalling pathways in human MMC lines, and compared the
effects with those induced in untransformed primary human
fibroblasts (Figure 3A). Consistent with the induction of MMC
death (Figure 1B), dual inhibition resulted in activation of the
critical apoptotic executioner, caspase-3, as indicated by
proteolytic processing of full-length caspase-3, in all four MMC
lines investigated. This effect was observed to a much lesser
extent after treatment with bortezomib or Eer1 alone.
Importantly, there was no evidence that dual p97/proteasome
inhibition activates caspase-3 in fibroblasts.
Activation of the Akt pathway, as indicated by
phosphorylation of Akt, is an important survival signal that has
been shown to occur in a proportion of MMCs [40]. In OPM-2
cells, which have constitutively active Akt (indicated by
phosphorylation) [46], treatment with bortezomib or Eer1
caused a mild decrease in Akt phosphorylation, while dual
inhibition abolished Akt phosphorylation. While phospho-Akt
was not detectable in the other MMC cell lines tested here,
dual inhibition also caused a substantial decrease in overall Akt
protein levels, whereas treatment with bortezomib or Eer1
alone had no or a moderate effect. Importantly, single or dual
inhibition had no effect on Akt levels in fibroblasts, providing
further evidence of the selective effects of dual p97/
proteasome inhibition on MMCs.
The observed changes in ER configuration (Figure 2) and
Akt signalling that we observed in MMCs prompted us to
investigate the impact of bortezomib and Eer1 on selected
protein translation control pathways in these cells.
Phosphorylation of the α-subunit of the eukaryotic translation
initiation factor 2 (eIF2α) on Ser51 results in attenuation of
protein translation and indicates activation of a PERK-
dependent UPR signalling that results in attenuated protein
translation [2,47]. We observed a moderate increase in eIF2α
phosphorylation in response to bortezomib in three of the four
MMC lines (OPM-2, RPMI-8226, KMS-11) investigated and
following treatment with Eer1 in two lines (RPMI-8226, U-266).
In contrast, dual inhibition invariably caused proteolytic
processing and/or loss of phosphorylated and total eIF2α,
which has been linked to terminal translational shut-down
rather than adaptive attenuation of translation [48-50]. In
fibroblasts, Eer1 alone and particularly dual inhibition with Eer1
and bortezomib induced phosphorylation of eIF2α on Ser51,
indicating activation of adaptive PERK signalling.
Phosphorylation of ribosomal protein S6 (S6P) correlates with
an increase in translation of mRNA transcripts that contain an
oligopyrimidine tract in their 5' untranslated regions [51]. Dual
p97/proteasome inhibition substantially decreased levels of
phosphorylated and total S6P in all MMCs lines, whereas
treatment with only bortezomib or Eer1 resulted in a reduction
in the levels of phosphorylated and total S6P in two of the four
MMC lines in each case (U-266 and KMS-11 for bortezomib;
OPM-2 and KMS-11 for Eer1). Once again, single or dual
inhibition had no detectable effect on S6P in fibroblasts. These
findings provide further evidence that considerable differences
can exist between MMCs in the way they respond to inhibition
of the proteasome or p97. They also indicate that separate
inhibition of the proteasome or p97 often results in mild effects
on protein translation control pathways in MMCs. Some of the
changes, such as increases in eIF2α phosphorylation, are
consistent with adaptive UPR signalling. In contrast, dual
inhibition invariably causes substantial changes that are
consistent with a terminal translational shut-down in these
pathways in MMCs. This interpretation fits with the loss of
ribosomes from the cytosolic surface of the ER, vacuolisation
of the ER, and the reduction in Akt levels described above. In
fibroblasts the effect of dual p97/protesome inhibition on these
pathways was very moderate and indicative of an adaptive
response.
In the light of the activation of caspase-3 that we observe
and the previously described role of JNK in bortezomib-induced
cell death [52], we next analysed JNK- and caspase-
dependence of MMC death induced by dual ERAD inhibition.
MMC lines were pre-incubated with the JNK inhibitor,
SP600125, and the pan-caspase inhibitor, zVADfmk and then
treated with Eer1 and bortezomib. We observed that apoptosis
of MMC lines induced by dual p97/proteasome inhibition
(Figure 3B) was JNK-independent (OPM-2 and KNS-11 cells)
or partly JNK dependent (RPMI 8226 and U-266 cells), and
caspase-dependent (RPMI 8226) or partly caspase-dependent
(OPM-2, U-266, KMS-11).
Structurally different inhibitors of p97 have comparable
effects in MMC lines and primary MMCs
Depletion of p97 by conditional gene knockout or RNAi
knockdown has limited utility for predicting the effects of
pharmacological p97 inhibition due to slow and incomplete
impact on p97 function [27]. To investigate whether the effects
of Eer1 described in the preceding sections are due to specific
inhibition of p97, and to exclude potential off-target effects
related to its chemical structure, we tested another recently
identified p97 inhibitor, DBeQ [26,29]. Staining of parental and
bortezomib-adapted AMO-1 MMCs with ER Tracker Blue-White
DPX demonstrated that the effect of DBeQ on ER configuration
was comparable to that of Eer1, with most of the ER presenting
as small vesicular or globular structures (Figure 4A).
Furthermore, combined treatment with both bortezomib and
DBeQ resulted in vacuolar transformation of the ER that was
very similar to the effect of combined Eer1 and bortezomib
treatment (Figure 4A). Similar to Eer1, DBeQ substantially
increased bortezomib-induced death of RPMI8226 cells and
primary MMCs co-cultured with IL-6 (Figure 4B and 4C). The
observation that the majority of the dying primary MMCs
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Figure 3.  Dual p97/proteasome inhibition deregulates key cell survival and protein translation control pathways in
MMCs.  (A) Immunoblotting for the indicated survival- and apoptosis-related proteins was carried out on whole cell extracts from
MMC lines and primary human fibroblasts prepared after treatment with either BTZ, Eer1, or both inhibitors, for 24h (14h in KMS-11
cells due to their higher apoptotic sensitivity to inhibitors). (B) Cell death induced by dual p97/proteasome inhibition is predominantly
caspase-dependent and JNK-independent. The proportion of live cells was determined after treatment with BTZ (5nM) and Eer1
(5µM) with or without the pan-caspase inhibitor zVADfmk (50µM) or the JNK inhibitor SP600125 (10µM) for 24h (36h for OPM-2
cells; all values are the mean and SEM of 3 experiments; *p<.05, **p<.001, two-sided student’s t-test).
doi: 10.1371/journal.pone.0074415.g003
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stained positive for Annexin V-FITC but excluded PI supports
the notion that MMC death induced by dual ERAD inhibition is
apoptotic. Thus, structurally different inhibitors of p97 have
comparable effects on ER configuration and viability of MMCs,
alone or in combination with bortezomib.
Discussion
The key finding of this paper is that all of the MMCs that we
have tested show dramatic changes to the ER in response to
dual inhibition of p97 and the proteasome, and that this is
accompanied by disruption of intracellular protein metabolism
and cell death. Importantly, the toxic effects of dual p97 and
proteasome inhibition are also observed for cell lines that are
insensitive to bortezomib. The effects of dual inhibition are
quite different from the effects of single inhibition of p97 or the
proteasome, adding significant information on the non-
redundant roles of p97 and the proteasome in maintaining the
integrity of the secretory apparatus.
Dual p97/proteasome inhibition causes changes in key
protein translation pathways in MMCs that are consistent with a
terminal translational shut-down. This interpretation is based on
the observation of proteolytic processing of eIF2α, and loss of
both phosphorylated and total S6P and Akt [48-50]. It is also
supported by the loss of ribosomes from the cytosolic surface
of the ER observed by TEM. In contrast, inhibition of either the
proteasome or p97 had a relatively modest impact on these
protein translation control pathways and did not result in loss of
ribosomes from the cytosolic surface of the ER. In particular,
bortezomib or p97 inhibition alone did not cause proteolytic
processing of eIF2α but moderately increased its
phosphorylation on Ser51 in some MMC lines, indicating
activation of adaptive PERK-dependent UPR signalling.
ER staining and electron microscopy showed that
proteasome inhibition had a very mild impact on the
appearance of the ER in MMCs, while p97 inhibitors caused
clear alterations to ER structure. The effect of p97 inhibition on
ER structure could reflect a hitherto unrecognised role for p97
in the metabolism of protein components of the ER membrane
or of proteins that play a role in maintaining ER integrity. Such
functions are suggested by the requirement of a p97/p37
complex for Golgi and ER maintenance in interphase [23]. The
dramatic transformation of the ER into very large vesicles that
we observed as a consequence of dual p97/proteasome
inhibition was unexpected. It is possible that the disruption of
ERAD increases drastically the amount of misfolded proteins
inside the ER, causing an increase in osmolarity in the ER
lumen that leads to an influx of water from the cytosol. Another
explanation might be that structural ER proteins are affected by
the disruption of protein translation. One mechanistic question
that arises from our findings is whether the translational shut-
down and the disruption of ER structure that result from dual
p97/proteasome inhibition are responsible for triggering cell
death or occur downstream from apoptotic signalling. The
previously described cleavage of eIF2α by caspase-3 might
seem to favour the latter scenario [48]. However, the pan-
caspase inhibitor zVADfmk did not block the formation of large
ER vacuoles after dual p97/proteasome inhibition.
Furthermore, at the time-point when cleavage of eIF2α was
evident in OPM-2 cells, the cells that presented with large ER
vacuoles and had lost ribosomes from the ER surface did not
yet show signs of apoptotic chromatin condensation. These
findings suggest that the structural changes to the ER and the
disruption of protein translation are not merely a consequence
of apoptotic signalling. We therefore favour a model in which
alterations of ER structure and protein translation play an
important early role in triggering cell death, but are also
aggravated further by the initiation of apoptotic signalling,
culminating in irreparable disruption of protein translation and
ER homeostasis.
Another important finding of this study is that the deleterious
effects of dual inhibition of p97 and the proteasome occur
preferentially in MMCs. In fibroblasts, dual p97/proteasome
inhibition failed to induce activation of caspase-3 and did not
affect levels of phosphorylated or overall Akt and S6P.
Moreover, dual inhibition did not induce proteolytic processing
of eIF2α in fibroblasts but increased its phosphorylation,
indicating PERK-dependent adaptive UPR signalling.
Furthermore, dual p97/proteasome inhibition was only
moderately toxic to primary PBMNCs. Taken together, these
findings indicate that dual p97/proteasome inhibition shows a
considerable degree of selectivity towards MMCs.
It is also noteworthy that the toxic effects of dual p97/
proteasome inhibition on MMCs were achieved at bortezomib
concentrations similar to steady-state plasma concentrations
maintained in patients after the early peak [53]. This is relevant
in the light of evidence that peripheral neuropathy, a major side
effect of bortezomib treatment in patients, may be caused by
off-target effects at high peak plasma concentrations [53,54].
Additional in vivo analysis will be required to elucidate potential
toxic and anti-myeloma effects of pharmacological p97
inhibition, alone and in combination with bortezomib. Systemic
in vivo studies are currently not possible due to the limited
solubility of Eer1 and DBeQ. However, the findings presented
here form a conceptual preclinical framework for combined
targeting of p97 and the proteasome as a potential novel
therapeutic approach in MM and provide a strong incentive for
developing p97 inhibitors that can be administered systemically
[27].
In contrast to the clinical effectiveness of proteasome
inhibitors in MM, they have shown disappointing results in most
other haematological malignancies and solid cancers. The
potent activity of p97 inhibitors in various cancer cells suggests
that p97 might be a more broadly useful target for
antineoplastic therapy than the proteasome [11,26,55]. One
possible reason for this is that inhibition of p97 disrupts ERAD
upstream of the proteasome, making its effects potentially
independent from variations in proteasomal capacity, which
can render cells insensitive to proteasome inhibition [5].
Inhibition of p97 may also be more effective than proteasome
inhibition in disrupting protein homeostasis because it
interferes with both HDAC6-mediated aggresome formation
and autophagosome maturation, which are potential
alternatives to proteasomal degradation of waste proteins
[13-15,26,33,56]. In addition, p97 inhibition directly regulates
intracellular levels of p53 and NFκB, which has been shown to
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mediate the toxic effects of Eer1 active against non-small cell
lung carcinoma (NSCLC), in which p97 is overexpressed [55].
The exceptional secretory load of MMCs, combined with their
high dependence on proteasomal and non-proteasomal protein
Figure 4.  Structurally different ERAD inhibitors have comparable effects in MMCs.  (A) Representative microscopic images of
parental and BTZ-adapted AMO-1 cells stained with ER Tracker Blue-White DPX after treatment for 18h with Eer1 (5µM), DBeQ
(5µM) or Eer1/DBeQ plus Bortezomib (5nM). The images show small to medium-sized globular/vesicular ER after p97 inhibition and
ER vacuolisation after dual ERAD inhibition. (B) The proportion of live RPMI8226 cells was determined after treatment with
bortezomib (10nM), DBeQ (10µM), or both, for 4h followed by drug wash-out and a further 20h incubation in culture medium (mean
and SEM of 3 experiments; *p<.05, **p<.001, two-sided student’s t-test). (C) Primary MMCs were isolated from a bone marrow
aspirate, incubated in culture medium containing IL-6 (10ng/ml) for 6h, followed by addition of bortezomib (5nM), DBeQ (5µM), or
both for 24h and analysis of apoptosis levels. Live cells (Annexin V-FITC and PI-negative) are shown in green in the left lower
quadrant, early apoptotic (Annexin V-FITC positive, right lower quadrant) and dead (Annexin V-FITC and PI-positive, right upper
quadrant) cells are shown in orange and red, respectively.
doi: 10.1371/journal.pone.0074415.g004
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degradation pathways, provides a plausible explanation for the
dramatic effects of combined p97 and proteasome inhibition on
the secretory apparatus that we report here. Considering that
p97 has key roles in a diverse range of cellular processes, it
will be important to investigate the combination of p97 inhibitors
with other classes of anti-neoplastic drugs in different types of
cancers [22,30,32,57].
Supporting Information
Figure S1.  Effect of single and dual p97/proteasome
inhibition on ER structure in MMC lines. OPM-2, U-266, and
KMS-11 cells were stained with ER Tracker Blue-White DPX
following treatment for 24h (14h for KMS-11) with BTZ (5nM),
Eer1 (5µM), or both. Representative confocal microscopic
images are shown.
(TIF)
Figure S2.  ER vacuolisation caused by dual ERAD
inhibition is not caused by overwhelming ER stress or
apoptotic signalling. OPM-2 cells were stained with ER
Tracker Blue-White DPX following treatment for 24h with high
doses of BTZ, Eer1, and tunicamycin, or BTZ+Eer1 after
pretreatment with the pan-caspase inhibitor zVADfmk.
(TIF)
Figure S3.  Representative transmission electron
miscrocopic images of OPM-2 cells treated with
Bortezomib (5nM) and Eer1 (5µM) for 24h.
(TIF)
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